Sample | Title | Value | Rank |
GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 97.8186 | 78 |
GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 110.328 | 79 |
GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 106.412 | 79 |
GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 80.6676 | 76 |
GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 123.663 | 80 |
GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 169.184 | 83 |
GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 137.466 | 81 |
GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 167.557 | 83 |
GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 128.956 | 80 |
GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 150.03 | 82 |